G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.
New cardio-oncology consultation for breast cancer patients, or
New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or
New cardio-oncology consultation for acute or chronic leukemia patients, or
New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or
Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators.
Minors less than 18 years old.
Inability or unwillingness to consent to participate
As above
Cohort
Prospective
anonymized data collection during programmed surveillance clinical follow up
Other interventionanonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
Cardiotoxicity
Any new cardiac event occurring during or after cancer treatment
New cardiovascular events
Heart failure, myocardial infarction, cardiac arrhythmias, syncope, coronary revascularization, heart transplant, cerebrovascular accident, peripheral arterial disease, hypertension, pulmonary hypertension. All events will be adjudicated according to standard clinical definitions.
Cardiovascular death.
Death during or after cancer treatment, adjudicated to cardiovascular causes by treating physicians.
Click on the lead sponsor to view all of their trials.
